KBIO News Alert Kalobios Pharmaceuticals Inc (KBIO) 1.83 01/06/2015
Post# of 64205
Posted On: 01/06/2015 6:59:51 PM
Kalobios Pharmaceuticals Inc (KBIO) 1.83 $KBIO
KaloBios Pharma -60% after KB001-A results disappoint
Seeking Alpha - at Seeking Alpha - 2 hrs 5 mins ago
KBIO: 1.83 (-0.02)
KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients
PR Newswire - 2 hrs 58 mins ago
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). While the data from this study showed KB001-A was generally safe and well-tolerated, the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs and symptoms (an indicator of reduction of the risk to develop pulmonary exacerbations) was not met.
KBIO: 1.83 (-0.02)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.83 (-0.02), GILD: 97.65 (+0.86), GERN: 3.12 (-0.13), ONTX: 4.25 (+0.05), CTIC: 2.30 (-0.06), BMY: 58.48 (-0.10), STML: 17.79 (-0.12), NVS: 91.67 (-0.78), MEIP: 4.29 (-0.21), CELGZ: 3.16 (+0.02), XLRN: 38.03 (-0.54)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 103.28 (-0.51), KBIO: 1.83 (-0.02), PFE: 31.42 (+0.26), ADMP: 6.21 (-0.01), GSK: 41.68 (-0.23), NVS: 91.67 (-0.78), FPRX: 23.00 (-3.92)
KaloBios names Robert A. Baffi to board
M2 - Mon Dec 01, 7:32AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) revealed on Monday the addition of Dr. Robert A. Baffi, Ph.D. to its board of directors.
BMRN: 90.28 (-2.83), KBIO: 1.83 (-0.02)
KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
PR Newswire - Mon Dec 01, 7:05AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Robert A. Baffi, Ph.D. to the KaloBios Board of Directors. Dr. Baffi is Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).
BMRN: 90.28 (-2.83), KBIO: 1.83 (-0.02)
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 93.89 (-2.18), KBIO: 1.83 (-0.02), AKRX: 36.42 (-0.70), MYL: 54.18 (-1.54)
KaloBios Announces Upcoming Scientific and Investor Conference Participation
PR Newswire - Tue Nov 11, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the Stifel 2014 Healthcare Conference in November, and that data on the company's KB004 program in hematologic malignancies will be presented in a poster session at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in early December.
KBIO: 1.83 (-0.02)
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 93.89 (-2.18), IPXL: 30.20 (-0.21), KBIO: 1.83 (-0.02), MYL: 54.18 (-1.54)
KaloBios Pharmaceuticals beats by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:38PM CST
KBIO: 1.83 (-0.02)
KaloBios Reports Third Quarter Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the third quarter of 2014.
KBIO: 1.83 (-0.02)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 31.42 (+0.26), INCY: 71.49 (-2.73), ONTX: 4.25 (+0.05), BMY: 58.48 (-0.10), GSK: 41.68 (-0.23), STML: 17.79 (-0.12), SNTA: 2.70 (-0.14), KBIO: 1.83 (-0.02), BPTH: 2.46 (-0.14), CELGZ: 3.16 (+0.02), NVS: 91.67 (-0.78)
NeoStem Announces Additions to Management
GlobeNewswire - Wed Nov 05, 6:46AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel cell based therapeutics, announced today the addition of three experienced leaders in the biotech industry to its management team. Harry Lam, Ph.D., Ann M. Daus, Ph.D., and Anna Crivici, Ph.D. bring a breadth of experience in leading high performing teams to meet operational goals.
KBIO: 1.83 (-0.02), NBS: 3.49 (-0.01)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.50 (-0.30), NEO: 4.11 (-0.08), AU: 9.74 (+0.57), FNHC: 25.37 (+1.30), AMS: 2.81 (-0.17), NYMX: 0.38 (+0.01), AMDA: 0.89 (-0.12), CVD: 104.61 (-0.39), GBIM: 7.71 (+0.02), RCAP: 13.01 (+0.07), KBIO: 1.83 (-0.02), COOL: 1.17 (-0.04), SAPE: 24.77 (-0.08), XTLB: 2.13 (+0.19), GERN: 3.12 (-0.13), ANIP: 52.21 (-3.77), BBLU: 1.32 (+0.25), NXTD: 2.24 (-0.10), AP: 18.20 (-0.72), ALQA: 5.29 (unch)
Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:25AM CDT
Cerulean Pharma (CERU) was a big mover last session, with shares surging nearly 31% on the day.
MNK: 93.89 (-2.18), KBIO: 1.83 (-0.02), AKRX: 36.42 (-0.70), CERU: 6.72 (+0.33)
Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
PR Newswire - Thu Aug 14, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels. The expression and function of EphA3 in the tumor microenvironment but not in adult normal tissues together with the favorable safety profile as observed thus far in a Phase 1-2 clinical study, where infusion reactions have been the most common adverse event, supports the development of KB004 (KaloBios' Humaneered® anti-EphA3 monoclonal antibody [mAb]) as a potential treatment for both hematologic and solid tumors.
KBIO: 1.83 (-0.02)
KaloBios (KBIO) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 9:04AM CDT
KaloBios (KBIO) Enters Oversold Territory
KBIO: 1.83 (-0.02)
Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:46AM CDT
Relypsa (RLYP) was a big mover last session, with shares rising over 13% on the day.
MNK: 93.89 (-2.18), KBIO: 1.83 (-0.02), AKRX: 36.42 (-0.70), RLYP: 31.63 (-0.75)
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on its current clinical programs and announced financial results for the second quarter of 2014.
KBIO: 1.83 (-0.02)
KaloBios Provides Update on KB001-A Partnership and Clinical Status
PR Newswire - Mon Jul 28, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.
KBIO: 1.83 (-0.02)
KaloBios Pharma -60% after KB001-A results disappoint
Seeking Alpha - at Seeking Alpha - 2 hrs 5 mins ago
KBIO: 1.83 (-0.02)
KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients
PR Newswire - 2 hrs 58 mins ago
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). While the data from this study showed KB001-A was generally safe and well-tolerated, the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs and symptoms (an indicator of reduction of the risk to develop pulmonary exacerbations) was not met.
KBIO: 1.83 (-0.02)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.83 (-0.02), GILD: 97.65 (+0.86), GERN: 3.12 (-0.13), ONTX: 4.25 (+0.05), CTIC: 2.30 (-0.06), BMY: 58.48 (-0.10), STML: 17.79 (-0.12), NVS: 91.67 (-0.78), MEIP: 4.29 (-0.21), CELGZ: 3.16 (+0.02), XLRN: 38.03 (-0.54)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 103.28 (-0.51), KBIO: 1.83 (-0.02), PFE: 31.42 (+0.26), ADMP: 6.21 (-0.01), GSK: 41.68 (-0.23), NVS: 91.67 (-0.78), FPRX: 23.00 (-3.92)
KaloBios names Robert A. Baffi to board
M2 - Mon Dec 01, 7:32AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) revealed on Monday the addition of Dr. Robert A. Baffi, Ph.D. to its board of directors.
BMRN: 90.28 (-2.83), KBIO: 1.83 (-0.02)
KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
PR Newswire - Mon Dec 01, 7:05AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Robert A. Baffi, Ph.D. to the KaloBios Board of Directors. Dr. Baffi is Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).
BMRN: 90.28 (-2.83), KBIO: 1.83 (-0.02)
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 93.89 (-2.18), KBIO: 1.83 (-0.02), AKRX: 36.42 (-0.70), MYL: 54.18 (-1.54)
KaloBios Announces Upcoming Scientific and Investor Conference Participation
PR Newswire - Tue Nov 11, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the Stifel 2014 Healthcare Conference in November, and that data on the company's KB004 program in hematologic malignancies will be presented in a poster session at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in early December.
KBIO: 1.83 (-0.02)
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 93.89 (-2.18), IPXL: 30.20 (-0.21), KBIO: 1.83 (-0.02), MYL: 54.18 (-1.54)
KaloBios Pharmaceuticals beats by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:38PM CST
KBIO: 1.83 (-0.02)
KaloBios Reports Third Quarter Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the third quarter of 2014.
KBIO: 1.83 (-0.02)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 31.42 (+0.26), INCY: 71.49 (-2.73), ONTX: 4.25 (+0.05), BMY: 58.48 (-0.10), GSK: 41.68 (-0.23), STML: 17.79 (-0.12), SNTA: 2.70 (-0.14), KBIO: 1.83 (-0.02), BPTH: 2.46 (-0.14), CELGZ: 3.16 (+0.02), NVS: 91.67 (-0.78)
NeoStem Announces Additions to Management
GlobeNewswire - Wed Nov 05, 6:46AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel cell based therapeutics, announced today the addition of three experienced leaders in the biotech industry to its management team. Harry Lam, Ph.D., Ann M. Daus, Ph.D., and Anna Crivici, Ph.D. bring a breadth of experience in leading high performing teams to meet operational goals. KBIO: 1.83 (-0.02), NBS: 3.49 (-0.01)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.50 (-0.30), NEO: 4.11 (-0.08), AU: 9.74 (+0.57), FNHC: 25.37 (+1.30), AMS: 2.81 (-0.17), NYMX: 0.38 (+0.01), AMDA: 0.89 (-0.12), CVD: 104.61 (-0.39), GBIM: 7.71 (+0.02), RCAP: 13.01 (+0.07), KBIO: 1.83 (-0.02), COOL: 1.17 (-0.04), SAPE: 24.77 (-0.08), XTLB: 2.13 (+0.19), GERN: 3.12 (-0.13), ANIP: 52.21 (-3.77), BBLU: 1.32 (+0.25), NXTD: 2.24 (-0.10), AP: 18.20 (-0.72), ALQA: 5.29 (unch)
Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:25AM CDT
Cerulean Pharma (CERU) was a big mover last session, with shares surging nearly 31% on the day.
MNK: 93.89 (-2.18), KBIO: 1.83 (-0.02), AKRX: 36.42 (-0.70), CERU: 6.72 (+0.33)
Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
PR Newswire - Thu Aug 14, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels. The expression and function of EphA3 in the tumor microenvironment but not in adult normal tissues together with the favorable safety profile as observed thus far in a Phase 1-2 clinical study, where infusion reactions have been the most common adverse event, supports the development of KB004 (KaloBios' Humaneered® anti-EphA3 monoclonal antibody [mAb]) as a potential treatment for both hematologic and solid tumors.
KBIO: 1.83 (-0.02)
KaloBios (KBIO) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 9:04AM CDT
KaloBios (KBIO) Enters Oversold Territory
KBIO: 1.83 (-0.02)
Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:46AM CDT
Relypsa (RLYP) was a big mover last session, with shares rising over 13% on the day.
MNK: 93.89 (-2.18), KBIO: 1.83 (-0.02), AKRX: 36.42 (-0.70), RLYP: 31.63 (-0.75)
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on its current clinical programs and announced financial results for the second quarter of 2014.
KBIO: 1.83 (-0.02)
KaloBios Provides Update on KB001-A Partnership and Clinical Status
PR Newswire - Mon Jul 28, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.
KBIO: 1.83 (-0.02)
(0)
(0)